Context. The increasing use of highly active antiretroviral therapies (HAARTs) has changed the course of AIDS-related illnesses and enhanced the quality of life of patients infected with human immunodeficiency virus (HIV) and may have changed the causes of deaths in patients with acquired immunodeficiency syndrome (AIDS).
INTRODUCTION
The past few years have been characterized by a marked and steady decline in both the number of deaths associated with acquired immunodeficiency syndrome (AIDS) and in estimates of AIDS-associated opportunistic illnesses. 1-s These changes represent a pivotal event since, for the first time, the course of the AIDS epidemic appears to have been slowed, at least in the industrialized countries.
The advances in treatment and prophylaxis of opportunistic infections, the availability of newer and more potent antiretroviral medications, and the expansion in the quality of supportive services for people infected with human immunodeficiency virus (HIV) have all contributed to this decline. 6 It was, however, mainly the use of highly active antiretroviral therapies (HAARTs) that appears to have made a crucial difference in controlling the spread of the AIDS epidemic.
HAARTs, which include nucleoside analogues in combination with non-nucleoside analogue reverse transcriptase inhibitors or protease inhibitors, can suppress viral replication and replenish CD4 cell counts. 7's In doing so, HAART boosts the otherwise severely immunosuppressed host defenses and plays a key role in enhancing both the quality and quantity of life for HW-infected people. 9' 1~ Furthermore, the use of HAART has been shown to reduce differentially the risk of developing specific AIDS-opportunistic infections, which represent the major clinical manifestation of HIV disease and were mainly responsible for patients' limited survival, n'12 This is important for it allows discontinuation of prophylactic regimens for opportunistic infections in those patients who regain enough functional immunity following HAART9 'u thus reducing the burden of additional medications in terms of drug toxicity and drug interactions.
At present, only a few studies have looked into the causes of death among patients with AIDS, and most of these studies were prior to the advent of HAART. n' 15-~8 More information is needed to understand better how the increasing use of HAART has been altering the clinical course of AIDS and changing the causes of death and how this can be translated into interventions targeted at the redefinition of end-of-life care for persons living with AIDS.
The aim of the present study was to provide a profile of causes of death in longterm care hospital patients with late-stage AIDS who expired at the Coler-Goldwater Memorial Hospital in New York City in 1995 and in [1998] [1999] , that is, immediately before and in the two most recent years after the availability of HAART.
METHODS
Coler-Goldwater Memorial Hospital, a large and comprehensive public longterm care facility in New York City with a 2,000-bed capacity, has active longterm care HW/AIDS units that total 176 beds.
The present study was a retrospective analysis conducted on 232 patients with late-stage AIDS who expired at the Coler-Goldwater Memorial Hospital in 1995 (pre-HAART availability group, n = 115) and in 1998-99, (post-HAART availability group, n = 117).
Of the 115 patients who expired in 1995, 97 (84%) were males and 18 (16%) were females; of the 117 patients who expired in 1998-1999, 87 (74%) were males, and 30 (26%) were females. In the pre-HAART 1995 group, 58 patients (51%) were drug nave, 45 patients (39%) had been treated with zidovudine (AZT) and/ or dideoxyinosine (DDI), and the remaining 12 patients (10%) had discontinued the treatment. In the post-HA_ART 1998-1999 group, 91 patients (78%) had been treated with a combination of antiretroviral therapies, whereas 26 patients (22%) did not receive HIV-specific therapy.
Rates of mortality were calculated by dividing the number of deaths that There were no further analyses of the medical records to corroborate the death certificate data.
Due to the nominal nature of the variables, the statistical analysis was done using the z test to assess the presence of any statistical differences in causes of death between patients who expired in 1995 and in 1998-1999. The Yates correction for continuity was introduced to obtain values of the z-test statistic more compatible with the theoretical standard normal distribution. 2~ When more than two sample groups or possible outcomes were compared, analysis of contingency tables using the Z 2 test statistic was performed. A P value less than .05 was considered statistically significant. Because of small numbers, causes of death, when appropriate, were grouped together. For instance, patients with AIDS who were considered to have expired from opportunistic infections such as Pneurnocystis carinii pneumonia (PCP), cerebral toxoplasmosis, and Mycobacterium avium complex infection were combined. Malignancies such as breast carcinoma, laryngeal carcinoma, Kaposi's sarcoma, and lymphomas were also combined as a cause of death. Finally, the pneumonia and sepsis categories captured patients who expired from a microbiologically specified cause of death and also those in whom a microbiological agent was not stated. As shown in Fig. 1 , the total number of deaths in the comparison years is almost alike, allowing for the direct comparison of numbers in each category of death (Fig. 2) . The similarity of the denominators in the comparison years was a chance finding. The number of patients with AIDS who expired because of 
DISCUSSION
As expected, the present study showed a decline of some magnitude, twofold, in the overall mortality rate among patients with late-stage AIDS who expired in 1995 and in 1998-1999. This decline is consistent with that previously reported in New York City 4 and in the US 5 and has been attributed mainly to the increased use of HAART. 1-3
Despite the fact that only 78% of the patients who died in the post-HAART availability group were able to be treated with antiretroviral combination therapies, the decrease in mortality rate was more than twofold. This might, at least in part, also be accounted for by other factors, such as improvements in both treatment and prophylaxis for opportunistic infections, as well as the overall services offered to HIV-infected persons. For instance, a slow decline in the incidence of some opportunistic infections in HIV-infected people had been observed even before the advent of HAART. 21~2 The impact of HAART on the course of the AIDS epidemic since 1996, however, has been so evident and sustained as to make minimal such contributions. Thus, the decrease in mortality rate observed in this late-stage AIDS population appears to be related to the overall effect of HAART, even though 22% of the patients were not treated with antiretroviral combination therapies. Moreover, further analysis between deaths of patients with AIDS who received HAART and deaths of patients who were unable to be treated would be important to reveal differences in causes of death in these two groups. Such an analysis is not possible with this data set because there are too few in the non-HAART group. A prospective study designed to address this question is needed to describe the reasons for this group of patients not receiving HAART.
Although these data depend on the accuracy by which causes of death were reported on the death certificates ~324 and therefore are limited, the study none- 
